Medigene with strong impulseIs medigene breaking out of trendchannel or simply overbought right now. CRS and RSI strong.
Came out of a bollinger squeeze and rising.
How can you tell if its a breakout from trend? Will it continue or fall back?
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.69USD
−17.86 MUSD
6.66 MUSD
28.40 M
About MEDIGENE AG
Sector
Industry
CEO
Selwyn Ho
Website
Headquarters
Martinsried
Employees (FY)
86
Founded
1996
ISIN
DE000A1X3W00
FIGI
BBG000F12VJ9
MediGene AG is a biotechnology company, which engages in developing innovative, complementary treatment platforms that target various types and stages of cancer. It focuses on the development of personalized T-cell based immunotherapies. It operates through the Immunotherapies and Other products segments. The company was founded by Ernst Ludwig Winnacker and Horst Domdey in June 1994 and is headquartered in Martinsried, Germany.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of MDGEF is 2.43 USD — it has decreased by 14.44% in the past 24 hours. Watch MediGene AG stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange MediGene AG stocks are traded under the ticker MDGEF.
MediGene AG is going to release the next earnings report on Aug 8, 2024. Keep track of upcoming events with our Earnings Calendar.
MDGEF stock is 16.87% volatile and has beta coefficient of 0.12. Track MediGene AG stock price on the chart and check out the list of the most volatile stocks — is MediGene AG there?
MDGEF earnings for the last quarter are −0.41 USD per share, whereas the estimation was −0.53 USD resulting in a 23.60% surprise. The estimated earnings for the next quarter are −0.30 USD per share. See more details about MediGene AG earnings.
MediGene AG revenue for the last quarter amounts to 3.65 M USD despite the estimated figure of 3.02 M USD. In the next quarter revenue is expected to reach 4.47 M USD.
Yes, you can track MediGene AG financials in yearly and quarterly reports right on TradingView.
MDGEF net income for the last quarter is −10.16 M USD, while the quarter before that showed −7.60 M USD of net income which accounts for −33.67% change. Track more MediGene AG financial stats to get the full picture.
Today MediGene AG has the market capitalization of 45.76 M, it has increased by 5.67% over the last week.
No, MDGEF doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, MDGEF shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade MediGene AG stock right from TradingView charts — choose your broker and connect to your account.
MDGEF reached its all-time high on Jan 3, 2001 with the price of 52.00 USD, and its all-time low was 1.29 USD and was reached on Nov 4, 2011. View more price dynamics on MDGEF chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
As of May 13, 2024, the company has 86.00 employees. See our rating of the largest employees — is MediGene AG on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So MediGene AG technincal analysis shows the neutral today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating MediGene AG stock shows the neutral signal. See more of MediGene AG technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on MediGene AG future price: according to them, MDGEF price has a max estimate of 3.21 USD and a min estimate of 2.39 USD. Watch MDGEF chart and read a more detailed MediGene AG stock forecast: see what analysts think of MediGene AG and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. MediGene AG EBITDA is −16.59 M USD, and current EBITDA margin is −249.04%. See more stats in MediGene AG financial statements.